The new label for Alecensa makes it the first targeted treatment available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.
With the FDA nod, Alecensa becomes the second molecularly targeted therapy to move into the adjuvant setting for non-small cell lung cancer.
Pakistan Army has approved promotion of 40 Brigadiers to Major General. According to ISPR, eleven of them were from Army Medical Corps. Pakistan Army promotion board, which met in Rawalpindi today ...